Wedbush Maintains Outperform on Arcus Biosciences, Raises Price Target to $41

Wedbush analyst Robert Driscoll has maintained an 'Outperform' rating on Arcus Biosciences (NYSE: RCUS) and increased the price target from $37 to $41. This adjustment reflects a positive outlook for the company.